Literature DB >> 17214965

A neutralizable epitope is induced on HGF upon its interaction with its receptor cMet.

Kisu Kim1, Youngmi Hur, En-Kyung Ryu, Jung-Hyo Rhim, Cha Yong Choi, Cheol-Min Baek, Jae-Ho Lee, Junho Chung.   

Abstract

A new conformational neutralizable epitope is created on heptocyte growth factor (HGF), when it interacts with its receptor, cMet. By immunizing rabbits with HGF-cMet complex, we successfully generated a monoclonal antibody (SFN68) that inhibits HGF-cMet interaction, and blocks the biological function mediated by HGF. To define the epitope, we screened out an epitope-mimicking peptide, KSLSRHDHIHHH, from a phage display of combinatorial peptide library. In molecular mimicry this peptide bound to cMet and inhibited HGF-cMet interaction. No humoral response was induced to this epitope-mimicking peptide when immunization was done with HGF alone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17214965     DOI: 10.1016/j.bbrc.2006.12.164

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Gremlin-1 induces BMP-independent tumor cell proliferation, migration, and invasion.

Authors:  Minsoo Kim; Soomin Yoon; Sukmook Lee; Seon Ah Ha; Hyun Kee Kim; Jin Woo Kim; Junho Chung
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

Review 2.  MET targeting: time for a rematch.

Authors:  Jonas P Koch; Daniel M Aebersold; Yitzhak Zimmer; Michaela Medová
Journal:  Oncogene       Date:  2020-02-07       Impact factor: 8.756

3.  An antibody reactive to the Gly63-Lys68 epitope of NT-proBNP exhibits O-glycosylation-independent binding.

Authors:  Yujean Lee; Hyori Kim; Junho Chung
Journal:  Exp Mol Med       Date:  2014-09-19       Impact factor: 8.718

Review 4.  Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.

Authors:  Ki-Hyun Kim; Hyori Kim
Journal:  Exp Mol Med       Date:  2017-03-24       Impact factor: 8.718

Review 5.  From rabbit antibody repertoires to rabbit monoclonal antibodies.

Authors:  Justus Weber; Haiyong Peng; Christoph Rader
Journal:  Exp Mol Med       Date:  2017-03-24       Impact factor: 8.718

6.  Preclinical development of a humanized neutralizing antibody targeting HGF.

Authors:  Hyori Kim; Sung Hee Hong; Jung Yong Kim; In-Chull Kim; Young-Whan Park; Song-Jae Lee; Seong-Won Song; Jung Ju Kim; Gunwoo Park; Tae Min Kim; Yun-Hee Kim; Jong Bae Park; Junho Chung; In-Hoo Kim
Journal:  Exp Mol Med       Date:  2017-03-24       Impact factor: 8.718

Review 7.  Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.

Authors:  Oshin Miranda; Mariya Farooqui; Jill M Siegfried
Journal:  Cancers (Basel)       Date:  2018-08-21       Impact factor: 6.639

Review 8.  Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk.

Authors:  Khadijeh Barzaman; Rana Vafaei; Mitra Samadi; Mohammad Hossein Kazemi; Aysooda Hosseinzadeh; Parnaz Merikhian; Shima Moradi-Kalbolandi; Mohammad Reza Eisavand; Houra Dinvari; Leila Farahmand
Journal:  Cancer Cell Int       Date:  2022-08-19       Impact factor: 6.429

Review 9.  Targeting the oncogenic Met receptor by antibodies and gene therapy.

Authors:  E Vigna; P M Comoglio
Journal:  Oncogene       Date:  2014-06-02       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.